Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.25 Insider Own0.50% Shs Outstand179.29M Perf Week1.74%
Market Cap13.65B Forward P/E392.47 EPS next Y0.19 Insider Trans-2.45% Shs Float178.78M Perf Month11.14%
Income-42.50M PEG- EPS next Q-0.06 Inst Own- Short Float4.24% Perf Quarter6.15%
Sales1.60B P/S8.52 EPS this Y-1.80% Inst Trans-0.06% Short Ratio5.55 Perf Half Y-15.09%
Book/sh17.15 P/B4.44 EPS next Y163.30% ROA-1.00% Target Price114.82 Perf Year-18.19%
Cash/sh4.02 P/C18.94 EPS next 5Y- ROE-1.40% 52W Range62.88 - 100.13 Perf YTD-10.58%
Dividend- P/FCF- EPS past 5Y19.40% ROI-1.50% 52W High-23.96% Beta1.28
Dividend %- Quick Ratio2.50 Sales past 5Y22.10% Gross Margin78.90% 52W Low21.09% ATR1.77
Employees2849 Current Ratio3.80 Sales Q/Q17.70% Oper. Margin-8.10% RSI (14)66.17 Volatility2.11% 2.67%
OptionableYes Debt/Eq0.28 EPS Q/Q516.30% Profit Margin-2.70% Rel Volume1.74 Prev Close76.14
ShortableYes LT Debt/Eq0.28 EarningsOct 23 AMC Payout- Avg Volume1.37M Price76.14
Recom1.90 SMA204.93% SMA507.15% SMA200-6.91% Volume0 Change0.00%
Nov-12-19Initiated SunTrust Buy $110
Oct-17-19Resumed BofA/Merrill Buy $90
May-23-19Resumed Citigroup Buy
Apr-09-19Resumed Raymond James Outperform
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18Initiated Wolfe Research Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $126
Aug-07-18Reiterated Stifel Buy $109 → $114
Aug-03-18Reiterated Stifel Buy $102 → $109
May-16-18Initiated Canaccord Genuity Buy $101
Jan-18-18Resumed Credit Suisse Outperform $113
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Aug-31-17Initiated Citigroup Buy $98
Aug-17-17Initiated Evercore ISI Outperform $100
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Nov-14-19 08:27AM  BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study PR Newswire
Nov-12-19 11:37AM  Buy Big Biotech But Not Gilead, Analyst Says Barrons.com
10:32AM  The Winds Have Changed for BioMarin TheStreet.com
09:30AM  REGN or BMRN: Which Is the Better Value Stock Right Now? Zacks
08:30AM  BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019 PR Newswire
Nov-08-19 02:33PM  Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
10:02AM  After sons rare disease diagnosis, father finds hope through film festival American City Business Journals
Nov-06-19 04:05PM  BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th PR Newswire
Nov-01-19 03:29AM  Edited Transcript of BMRN earnings conference call or presentation 23-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-30-19 09:23AM  Can The Uptrend Continue for BioMarin Pharmaceutical? Zacks
Oct-29-19 09:00AM  BioMarin (BMRN) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Oct-24-19 12:50PM  BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3 Zacks
10:03AM  BioMarin Stock Rises on Earnings Beat Barrons.com
09:30AM  HZNP or BMRN: Which Is the Better Value Stock Right Now? Zacks
Oct-23-19 05:55PM  BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings and Revenue Estimates Zacks
04:05PM  BioMarin Announces Third Quarter 2019 Financial Results PR Newswire
07:54AM  The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga
Oct-22-19 11:32AM  Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More Zacks
Oct-20-19 08:08AM  The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-19-19 09:14AM  BioMarin Pharmaceutical (NASDAQ:BMRN) Is Carrying A Fair Bit Of Debt Simply Wall St.
Oct-18-19 06:23PM  BioMarin Pharmaceutical Inc. (BMRN): Hedge Funds Fumbled the Ball Insider Monkey
Oct-17-19 10:41AM  4 Biotech Stocks That Are Set to Rally, Analyst Says Barrons.com
Oct-16-19 10:33AM  BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Oct-09-19 08:31AM  BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET PR Newswire
Oct-07-19 08:31AM  BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer PR Newswire
Oct-01-19 05:10PM  It's not just Google: 'Fierce' competition for tech talent is pushing median salaries past $200K at many Silicon Valley companies American City Business Journals
01:43PM  Biotech Roundtable: How to Invest in Medicines Future Barrons.com
08:30AM  BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York PR Newswire
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
11:00AM  Healthcare: Political Uncertainties Have Weighed on the Sector Morningstar
Sep-27-19 07:56AM  The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave Benzinga
Sep-26-19 08:31AM  BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU PR Newswire
Sep-20-19 01:10PM  Gilead, AbbVie Are Innovative, but May Be Underappreciated GuruFocus.com
Sep-15-19 03:28PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 13 GuruFocus.com
Sep-13-19 08:12AM  Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Overpaying Its CEO? Simply Wall St.
Sep-09-19 04:05PM  BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York PR Newswire
Aug-31-19 09:31AM  BioMarin (BMRN) Down 7.3% Since Last Earnings Report: Can It Rebound? Zacks
Aug-28-19 08:30AM  BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York PR Newswire
Aug-14-19 12:06PM  Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 31% Discount? Simply Wall St.
Aug-13-19 07:00AM  The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook American City Business Journals
Aug-08-19 04:29PM  6 Underperforming Stocks in Gurus' Portfolios GuruFocus.com
10:33AM  Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval Zacks
10:25AM  Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-19 10:45AM  BioMarin's Roller Coaster Continues Motley Fool
Aug-02-19 11:23AM  Biomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript Motley Fool
10:52AM  BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss Zacks
09:15AM  BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Arent Worried Barrons.com
Aug-01-19 06:05PM  BioMarin Pharmaceutical (BMRN) Lags Q2 Earnings and Revenue Estimates Zacks
04:05PM  BioMarin Announces Second Quarter 2019 Financial Results PR Newswire
Jul-31-19 09:15AM  Rate Cut Wait Almost Over Zacks
Jul-29-19 09:08AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Jul-25-19 10:34AM  BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Jul-16-19 10:16AM  Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order and more American City Business Journals
08:30AM  BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET PR Newswire
Jul-12-19 02:25PM  Shake-Up in Big Weed Motley Fool
Jul-10-19 05:57AM  BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit Simply Wall St.
05:43AM  JP Morgan: 2 Gene Therapy Stocks to Buy Now TipRanks
Jul-09-19 10:40AM  BioMarin (BMRN) to File for Hemophilia A Candidate in Q4 Zacks
08:31AM  BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors PR Newswire
06:00AM  3 Top Biotech Stocks to Buy in July Motley Fool
Jul-08-19 04:18PM  Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals Investor's Business Daily
12:58PM  Here's Why Sangamo Therapeutics Is Surging Today Motley Fool
09:55AM  Sarepta Stock Up Almost 40% This Year So Far: Here's Why Zacks
08:01AM  BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe PR Newswire
07:30AM  Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others American City Business Journals
Jul-01-19 06:00AM  Healthcare: Drugmakers and Providers Look Attractive Morningstar
Jun-26-19 08:31AM  BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019 PR Newswire
Jun-25-19 11:09AM  8 Stocks May Jump on Takeovers as Market Nears Peak Investopedia
09:33AM  Despite Recent Volatility, Biotech Stocks Look Poised to Pop Investopedia
Jun-24-19 11:04AM  BioMarin Gets $15M From Pfizer on Talzenna's European Nod Zacks
08:33AM  Pfizer's Talzenna Gets Approval in Europe for Breast Cancer Zacks
Jun-21-19 11:30AM  BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation PR Newswire
Jun-17-19 01:52PM  Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up Investor's Business Daily
Jun-13-19 09:08PM  Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license American City Business Journals
Jun-12-19 07:30AM  9 major Bay Area tech employers pay a typical worker more than $200K per year American City Business Journals
Jun-11-19 04:40PM  'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases American City Business Journals
10:24AM  Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN) Insider Monkey
Jun-10-19 09:03AM  Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit? Simply Wall St.
Jun-09-19 12:09PM  3 Top Growth Stocks to Buy in June Motley Fool
Jun-06-19 10:33AM  BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady Zacks
Jun-05-19 08:30AM  BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA PR Newswire
Jun-04-19 08:30AM  BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome PR Newswire
Jun-02-19 11:08AM  5 Best-Rated Stocks To Buy Amid Selloff TipRanks
May-31-19 10:39AM  Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous? Motley Fool
May-29-19 10:52AM  BioMarin Announces Data on Hemophilia Candidate, Shares Fall Zacks
10:22AM  Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion Zacks
May-28-19 07:46PM  How BioMarin May Revolutionize the Hemophilia Treatment Market Motley Fool -5.13%
05:35PM  A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last? American City Business Journals
05:00PM  What Happened in the Stock Market Today Motley Fool
04:45PM  BioMarins 2019 Stock Gains Erased After Release of Gene Therapy Data Barrons.com
04:22PM  This Biotech Had Positive Data In Gene Therapy But It Wasn't Enough Investor's Business Daily
10:21AM  BioMarin's hemophilia gene therapy data shows promise Reuters
07:11AM  BioMarin says hemophilia gene therapy meets certain criteria in late-stage trial Reuters
06:55AM  BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe PR Newswire
06:50AM  BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A PR Newswire
May-27-19 04:00PM  BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update PR Newswire
May-26-19 09:00AM  3 Big Biotech Stocks That Warren Buffett Might Like Motley Fool
May-22-19 10:02AM  BioMarin Stock Is a Buy, With or Without Hemophilia Treatment, J.P. Morgan Says Barrons.com
May-16-19 08:42AM  BioMarin (BMRN) in Focus: Stock Moves 7.5% Higher Zacks
08:30AM  BioMarin to Participate in 2019 RBC Capital Markets Global Healthcare Conference on May 21 in New York City PR Newswire
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerOct 25Option Exercise21.515,000107,550332,520Oct 29 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 25Sale69.555,000347,750327,520Oct 29 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 27Option Exercise21.511,00021,510327,520Sep 30 08:16 PM
LAWLIS V BRYANDirectorSep 17Option Exercise21.513,75080,66327,340Sep 18 06:47 PM
LAWLIS V BRYANDirectorSep 17Sale74.473,750279,26323,590Sep 18 06:47 PM
HERON ELAINE JDirectorAug 07Option Exercise63.101,55397,99447,668Aug 08 07:34 PM
LAWLIS V BRYANDirectorJun 17Option Exercise21.513,75080,66327,340Jun 19 12:27 PM
LAWLIS V BRYANDirectorJun 17Sale81.083,750304,05023,590Jun 19 12:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Option Exercise14.3910,000143,900336,520May 14 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Sale82.5210,000825,193326,520May 14 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 09Option Exercise14.394,00057,560330,520May 13 07:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 09Sale81.974,000327,888326,520May 13 07:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise14.394,00057,560330,520May 09 08:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale82.164,000328,625326,520May 09 08:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 26Option Exercise14.393,00043,170329,211Apr 30 08:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 26Sale82.883,000248,640326,211Apr 30 08:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 16Option Exercise21.511,00021,510326,211Apr 18 07:25 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 12Option Exercise14.394,00057,560329,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 12Sale89.124,000356,480325,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 11Option Exercise14.391,00014,390325,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 08Option Exercise14.393,00043,170327,211Apr 09 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 08Sale91.873,000275,598324,211Apr 09 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.393,00043,170327,211Apr 09 06:10 PM
Mueller BrianSVP, Corporate ControllerApr 05Sale94.002,953277,58213,660Apr 09 06:12 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Sale93.373,000280,114324,211Apr 09 06:10 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerApr 01Sale89.0013,4731,199,09747,510Apr 03 01:17 PM
LAWLIS V BRYANDirectorMar 27Option Exercise14.392,15030,93921,310Mar 29 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 27Option Exercise14.391,00014,390324,211Mar 29 06:07 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 27Sale90.001009,00060,983Mar 29 06:19 PM
LAWLIS V BRYANDirectorMar 27Sale89.762,150192,98419,160Mar 29 06:30 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 26Sale89.183,656326,02547,475Mar 27 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 25Option Exercise14.394,00057,560327,211Mar 26 07:51 PM
FUCHS HENRY JPresident, Worldwide R&DMar 25Sale87.865,932521,186124,536Mar 26 08:20 PM
Davis George EricEVP, General CounselMar 25Sale87.863,363295,47371,890Mar 26 08:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 25Sale87.864,000351,440323,211Mar 26 07:51 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 21Sale89.984,519406,63454,729Mar 25 05:18 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 19Option Exercise14.391,00014,390336,338Mar 21 05:01 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 19Sale93.073,728346,96559,248Mar 21 05:00 PM
Davis George EricEVP, General CounselMar 19Sale93.927,907742,62578,562Mar 21 05:00 PM
FUCHS HENRY JPresident, Worldwide R&DMar 18Sale94.099,597902,982136,304Mar 19 08:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise14.394,00057,560339,338Mar 19 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale94.404,000377,600335,338Mar 19 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Option Exercise14.393,00043,170331,701Mar 14 02:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Sale93.423,000280,253328,701Mar 14 02:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Option Exercise14.394,00057,560332,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Sale91.444,000365,770328,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Option Exercise14.395,00071,950333,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Sale88.965,000444,780328,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 07Option Exercise14.394,00057,560332,701Mar 08 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 07Sale90.784,000363,120328,701Mar 08 08:34 PM
FUCHS HENRY JPresident, Worldwide R&DMar 04Sale95.002,196208,620142,504Mar 06 05:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 27Option Exercise14.394,00057,560292,290Feb 28 08:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 27Sale91.784,000367,120288,290Feb 28 08:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 21Option Exercise14.393,00043,170291,290Feb 22 06:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 21Sale90.123,000270,360288,290Feb 22 06:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 14Option Exercise14.394,00057,560292,290Feb 15 07:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 14Sale95.204,000380,800288,290Feb 15 07:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 05Option Exercise14.394,00057,560292,290Feb 07 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 05Sale98.634,000394,520288,290Feb 07 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 22Option Exercise14.393,00043,170291,290Jan 24 07:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 22Sale96.823,000290,460288,290Jan 24 07:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Option Exercise14.394,00057,560292,290Jan 15 07:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Sale93.794,000375,160288,290Jan 15 07:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise14.393,00043,170291,290Jan 11 03:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale90.553,000271,650288,290Jan 11 03:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Option Exercise14.396,00086,340294,290Jan 10 06:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Sale91.596,000549,523288,290Jan 10 06:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Option Exercise14.393,00043,170291,290Jan 09 02:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Sale87.583,000262,740288,290Jan 09 02:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Option Exercise14.393,00043,170291,290Jan 02 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale84.043,000252,120288,290Jan 02 05:24 PM
LAWLIS V BRYANDirectorDec 27Option Exercise14.392,15030,93921,310Dec 28 06:23 PM
LAWLIS V BRYANDirectorDec 27Sale82.532,150177,44019,160Dec 28 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Option Exercise14.394,00057,560292,290Dec 27 05:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Sale80.504,000322,000288,290Dec 27 05:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 14Option Exercise17.862,00035,720290,290Dec 18 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 14Sale92.642,000185,280288,290Dec 18 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 12Option Exercise17.862,00035,720290,290Dec 14 02:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 12Sale93.122,000186,240288,290Dec 14 02:44 PM
open in yahoo | open in reuters | open in google